INNL Innocoll Holdings

1.04
0  -13%
Previous Close 1.19
Open 1.14
Price To book 0.00
Market Cap 30.94M
Shares 29,748,000
Volume 1,141,172
Short Ratio 1.35
Av. Daily Volume 1,176,230

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data did not meet endpoints - November 3, 2016.
Cogenzia
Diabetic foot ulcer infections
Refusal to file letter received December 29, 2016. Intends to initiate short-term Pharmacokinetic study and several short-term non-clinical studies before resubmitting NDA filing.
XaraColl
Post-operative pain

Latest News

  1. Lifshitz & Miller LLP Announces Investigation of Aratana Therapeutics, Inc., FXCM Inc., Innocoll Holdings plc, Momenta Pharmaceuticals, Inc., Omnicom Group Inc., Perrigo Company plc, Santander Consumer USA Holdings Inc. and The Interpublic
  2. INNOCOLL HOLDINGS PLC Financials
  3. INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Innocoll Holdings plc, and Encourages Investors with Losses Exceeding $100,000 to Contact the Firm
  4. INNL UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Innocoll Holdings plc and a Lead Plaintiff Deadline of March 27, 2017
  5. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Innocoll Holdings plc, and Encourages Investors with Losses to Contact the Firm
  6. DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Innocoll Holdings, plc (INNL) & Lead Plaintiff Deadline: March 27, 2017
  7. Orphan Drug Status and Investor Confidence Boost Stock Prices of Moleculin Biotech and Innocoll Holdings
  8. SHAREHOLDER NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Innocoll Holdings plc, and Encourages Investors with Losses Exceeding $100,000 to Contact the Firm
  9. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of Innocoll Holdings plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 27, 2017 – INNL
  10. Innocoll Holdings (INNL) Shows Strength: Stock Up 36.6%
  11. Innocoll downgraded by Stifel
  12. Innocoll reports 4Q loss
  13. Innocoll reports 4Q loss
  14. INNOCOLL HOLDINGS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
  15. Innocoll Holdings plc Announces Fourth Quarter and Full-Year 2016 Financial and Operating Results and Provides Corporate Update
  16. Innocoll Holdings Announces Statement re: Possible Offer
  17. Innocoll Holdings Announces Statement re: Possible Offer
  18. CLASS PERIOD UPDATE FOR INNL SHAREHOLDERS: Lundin Law PC Announces Securities Class Action Lawsuit against Innocoll Holdings plc, and Encourages Investors with Losses to Contact the Firm
  19. EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Innocoll Holdings plc - INNL
  20. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Innocoll Holdings plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 27, 2017 – INNL
  21. IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Innocoll Holdings plc, and Encourages Investors with Losses Exceeding $100,000 to Contact the Firm
  22. DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Innocoll Holdings, plc (INNL) and Lead Plaintiff Deadline: March 27, 2017
  23. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Innocoll Holdings Public Limited Company of Class Action Lawsuit and Upcoming Deadline – INNL
  24. Innocoll Receives Refusal to File Letter from U.S. FDA for XARACOLL® (bupivacaine HCl collagen-matrix implants) New Drug Application
  25. Innocoll Holdings plc Announces Third Quarter 2016 Financial and Operating Results and Provides Corporate Update
  26. Innocoll to Report Third Quarter 2016 Financial Results and Host Webcast and Conference Call on November 22, 2016
  27. Innocoll Announces Top-Line Data From Phase 3 Trials With COGENZIA and NDA Submission for XARACOLL
  28. Innocoll Holdings plc Announces Second Quarter 2016 Financial and Operating Results and Provides Corporate Update
  29. Innocoll to Report Second Quarter 2016 Financial Results and Host Webcast and Conference Call on August 17, 2016
  30. Innocoll Holdings plc to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
  31. Innocoll Holdings plc Announces the Completion of Enrollment in Two Pivotal Phase 3 Clinical Trials of COGENZIA for the Treatment of Diabetic Foot Infections
  32. Innocoll Holdings plc Announces Closing of Public Offering
  33. Innocoll Holdings plc Announces Pricing of Public Offering of Ordinary Shares
  34. Innocoll Holdings plc to Present at the JMP Securities Life Sciences Conference
  35. Innocoll Holdings plc Announces Proposed Public Offering of Ordinary Shares
  36. Innocoll to Host Live Webcast on Top-Line Results from Two Pivotal Phase 3 Trials of XARACOLL® (bupivacaine-collagen bioresorbable implant) in Postoperative Pain Relief
  37. Innocoll Announces XARACOLL® (bupivacaine-collagen bioresorbable implant) Meets Primary Endpoint in Both Pivotal Phase 3 Trials in Postoperative Pain Relief
  38. Innocoll Holdings plc Announces First Quarter 2016 Financial and Operating Results and Provides Corporate Update